DOCSLIB.ORG

PROVIRON® (Pro-VAI-Ron) Mesterolone

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PROVIRON® (Pro-VAI-Ron) Mesterolone PROVIRON® (Pro-VAI-ron) mesterolone Consumer Medicine Information WHAT IS IN THIS Proviron is for use in male patients Do not use this medicine after the LEAFLET only. expiry date printed on the pack and blister. Ask your doctor if you have any The expiry date is printed on the This leaflet answers some common questions about why this medicine carton and on each blister after questions about Proviron. has been prescribed for you. "EXP" (e.g. 11 18 refers to Your doctor may have prescribed it It does not contain all of the available November 2018). The expiry date for another reason. information. refers to the last day of that month. If It does not take the place of talking to it has expired return it to your your doctor or pharmacist. pharmacist for disposal. All medicines have risks and BEFORE YOU USE Do not use this medicine if the benefits. Your doctor has weighed PROVIRON packaging is torn or shows signs of the risks of you taking Proviron tampering. against the benefits they expect it If the packaging is damaged, return it will have for you. When you must not take it to your pharmacist for disposal. If you have any concerns about If you are not sure whether you Do not take Proviron if you have should start taking this medicine, talk taking this medicine, ask your an allergy to: doctor or pharmacist. to your doctor. • mesterolone, the active ingredient Keep this leaflet with the medicine. in Proviron Before you start to take it You may need to read it again. • any of the ingredients listed at the end of this leaflet. Tell your doctor if you have allergies to any other medicines, Some of the symptoms of an allergic foods, preservatives or dyes. reaction may include: WHAT PROVIRON IS Before starting Proviron, your doctor • shortness of breath USED FOR will conduct an examination of your • wheezing or difficulty breathing prostate. Your doctor will also note • Proviron is used to replace swelling of the face, lips, tongue your medical history and perform testosterone in men with or other parts of the body other tests including a blood test. hypogonadism. Male hypogonadism • rash, itching or hives on the skin. is a condition when the body does Tell your doctor if you have or Do not take Proviron if you have: have had any of the following not produce enough testosterone. • prostate cancer medical conditions: Testosterone is a natural male • previous or existing liver tumours • prostate disease hormone, known as an androgen, • • liver disease which controls normal sexual male breast cancer • development in men. • high blood calcium levels heart or blood vessel disease • high blood pressure Testosterone is essential for the • development and maintenance of the kidney disease male reproductive organs as well as • difficulty passing urine other male characteristics, such as • migraines hair growth, deep voice, sexual drive, • epilepsy muscle mass and body fat • diabetes distribution. PROVIRON® Published by MIMS/myDr March 2013 1 • sleep apnoea (abnormal pauses in HOW TO TAKE If you forget to take it breathing during sleep) PROVIRON If it is almost time for your next • polycythaemia (a blood disorder dose, skip the dose you missed and where too many red blood cells Follow all directions given to you take your next dose when you are are being produced) by your doctor or pharmacist meant to. • porphyria a rare metabolising carefully. disorder They may differ from the Otherwise, take it as soon as you information contained in this leaflet. remember, and then go back to If you have not told your doctor taking it as you would normally. about any of the above, tell If you do not understand the him/her before you start taking instructions printed on the pharmacist Do not take a double dose to make Proviron. label, ask your doctor or pharmacist up for the dose that you missed. Use of androgens for reasons other for help. If you are not sure what to do, ask than what your doctor prescribed your doctor or pharmacist. carries a serious health risk and is How much to take If you have trouble remembering strongly discouraged. Your doctor or pharmacist will tell when to take your medicine, ask Use of Proviron during puberty can you how much and how often you your pharmacist for some hints. stunt your growth. Your doctor can should take Proviron. discuss with you the risks and For Proviron to work best it is very If you take too much benefits involved. important to take it exactly as your (overdose) doctor tells you. Taking other medicines Immediately telephone your The usual treatment consists of 1-2 doctor, or the Poisons Information Tell your doctor if you are taking tablets three times per day. After a Centre (telephone 13 11 26), or go any other medicines, including few months of treatment, your doctor to the Accident and Emergency those that you buy without a may decrease the dose to 1 tablet two department at your nearest hospital, if you think you or prescription from your pharmacy, to three times a day. supermarket or health food shop. anyone else may have taken too Do not exceed the recommended much Proviron. Do this even if Some medicines and Proviron may dose your doctor has prescribed for there are no signs of discomfort or interfere with each other. These you as this can increase your risk of poisoning. include: side effects. You may need urgent medical • phenobarbital or phenytoin, attention. medicines used to treat seizures How to take it Excessive use of hormonal • cyclosporin, a medicine used to substances such as Proviron has been suppress the immune system Swallow the tablet whole with associated with liver abnormalities, water. • medicines used for diabetes tumours, changes to blood lipids, • thyroxine, a medicine used to increased risk of heart disease, replace low thyroid levels When to take it reduced glucose tolerance, decreased testosterone levels, enlargement of • oral anticoagulants such as Take your medicine at about the male breast tissue, stunted growth, warfarin, 'blood thinning' same time each day medications to treat or prevent psychiatric disturbances, acute Taking it at the same time each day blood clots withdrawal syndrome, vomiting will have the best effect. It will also blood or blood in stools and tendon • neuromuscular blockers such as help you remember when to take it. It damage. anaesthetics, medicines used to does not matter if you take this cause temporary paralysis medicine before or after food. These medicines may be affected by Proviron or may affect how well it How long to take it works. You may need different amounts of your medicines, or you Continue taking your medicine for as may need to take different medicines. long as your doctor tells you. This medicine helps control your Your doctor and pharmacist have condition, but does not cure it. It is more information on medicines to be important to keep taking your careful with or avoid while taking medicine even if you feel well. this medicine. PROVIRON® Published by MIMS/myDr March 2013 2 WHILE YOU ARE SIDE EFFECTS Hormonal substances such as TAKING PROVIRON Proviron may quicken the growth of Tell your doctor or pharmacist as existing hormone dependent tissues soon as possible if you do not feel and tumours If you are over 65 years Things you must do well while you are taking Proviron. of age, you may have an increased All medicines can have side effects. risk of developing prostatic If you are about to be started on Sometimes they are serious, most of hyperplasia (enlargement of the any new medicine, remind your the time they are not. You may need prostate) and prostatic cancer. doctor and pharmacist that you medical attention if you get some of are taking Proviron. Tell your doctor or pharmacist if the side effects. you notice anything that is making Tell any other doctors, dentists, you feel unwell. and pharmacists who treat you Do not be alarmed by the following that you are taking this medicine. lists of possible side effects. You Other side effects not listed above may not experience any of them. may also occur in some people. If you are going to have surgery, tell the surgeon or anaesthetist that Ask your doctor or pharmacist to you are taking this medicine. answer any questions you may have. It may affect other medicines used during surgery. Tell your doctor or pharmacist if AFTER TAKING you notice any of the following and PROVIRON Keep all of your doctor's they worry you: appointments so that your progress • headache can be checked. Storage Your doctor may do some tests (such • fluid retention as blood tests and regular • breast enlargement Keep your tablets in the pack until examinations of the prostate) from • increased sexual drive it is time to take them. time to time to make sure the If you take the tablets out of pack, • psychiatric disturbances such as medicine is working and to check for they may not keep well. depression, aggression, increased unwanted side effects. or decreased energy levels, Keep your tablets in a cool dry If you experience prolonged elation or irritability place where the temperature stays stomach pain, blood in the stools or • acne below 30°C. vomit, or yellowing of the skins • excessive hairiness Do not store it or any other and eyes during treatment with • medicine in the bathroom, near a Proviron, tell your doctor premature puberty sink, or on a window-sill. immediately • stunted growth There have been cases reported of Tell your doctor immediately, or Do not leave it in the car.
Load more

Recommended publications
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Effects of Androgenic-Anabolic Steroids on Apolipoproteins and Lipoprotein (A) F Hartgens, G Rietjens, H a Keizer, H Kuipers, B H R Wolffenbuttel
    253 Br J Sports Med: first published as 10.1136/bjsm.2003.000199 on 21 May 2004. Downloaded from ORIGINAL ARTICLE Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a) F Hartgens, G Rietjens, H A Keizer, H Kuipers, B H R Wolffenbuttel ............................................................................................................................... Br J Sports Med 2004;38:253–259. doi: 10.1136/bjsm.2003.000199 Objectives: To investigate the effects of two different regimens of androgenic-anabolic steroid (AAS) administration on serum lipid and lipoproteins, and recovery of these variables after drug cessation, as indicators of the risk for cardiovascular disease in healthy male strength athletes. Methods: In a non-blinded study (study 1) serum lipoproteins and lipids were assessed in 19 subjects who self administered AASs for eight or 14 weeks, and in 16 non-using volunteers. In a randomised double blind, placebo controlled design, the effects of intramuscular administration of nandrolone decanoate (200 mg/week) for eight weeks on the same variables in 16 bodybuilders were studied (study 2). Fasting serum concentrations of total cholesterol, triglycerides, HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2- C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and lipoprotein (a) (Lp(a)) were determined. Results: In study 1 AAS administration led to decreases in serum concentrations of HDL-C (from 1.08 (0.30) to 0.43 (0.22) mmol/l), HDL2-C (from 0.21 (0.18) to 0.05 (0.03) mmol/l), HDL3-C (from 0.87 (0.24) to 0.40 (0.20) mmol/l, and Apo-A1 (from 1.41 (0.27) to 0.71 (0.34) g/l), whereas Apo-B increased from 0.96 (0.13) to 1.32 (0.28) g/l.
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • Prohibited List
    PROHIBITED LIST This List shall come into effect on 1 January 201X THE 201X PROHIBITED LIST Valid 1 January 201X In accordance with ARCI-011-015/ARCI-025-015 all substances in the categories below shall be strictly prohibited unless otherwise noted. Any reference to substances in this section does not alter the requirements for testing concentrations in race day samples. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES Nothing in this list shall alter the requirements of post-race testing. S0. NON-APPROVED SUBSTANCES Any pharmacologic substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human or veterinary use (e.g., drugs under pre-clinical or clinical development, discontinued drugs, and designer drugs) is prohibited at all times. S00. THERAPEUTIC SUBSTANCES Therapeutic substances that are not otherwise prohibited pursuant to this list are permitted provided such substances: Have current approval for use in human, horse, or other animal by any governmental regulatory health authority in the jurisdiction where the horse is located S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) 1.1. Exogenous* AAS, including: 1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α- androst-1-ene-3,17-dione); bolandiol (estr-4-ene-3β,17β-diol ); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol
    [Show full text]
  • Mesterolone (Proviron) Induces Low Sperm Quality with Reduction in Sex Hormone Profile in Adult Male Sprague Dawley Rats Testis
    Scientific Research and Essay Vol. 4 (4), pp. 320-327, April, 2009 Available online at http://www.academicjournals.org/SRE ISSN 1992-2248 © 2009 Academic Journals Full Length Research Paper Mesterolone (Proviron) induces low sperm quality with reduction in sex hormone profile in adult male Sprague Dawley rats testis Shittu Lukeman A. J.1*, Shittu Remilekun K.2, Osinubi Abraham A. A.3 and Tayo Adetokunbo A.4 1Department of Anatomical Sciences, University of Abuja, College of Health Sciences, Gwagwalada, Abuja, Nigeria. 2Medical Microbiology Unit, Bolomedics Laboratories, Egbeda, Lagos, Nigeria. 3Department of Anatomy, College of Medicine, University of Lagos, Idi-araba, Lagos, Nigeria. 4Department of Obstetrics and Gynecology, Lagos State University, College of Medicine, Ikeja, Lagos, Nigeria. Accepted 16 February, 2009 Anabolic-androgenic steroid compounds are one of the most widely abused drugs by athletes and muscle builders with the goal of improving performance/muscle mass. However, increasing concern has been expressed because these compounds not only offer unappreciable benefits to infertile and subfertile males, but also might have deleterious effects on both human and animal physiology including sperm quality. In addition, there is the conflicting outcome of AAS usage in the clinical settings with its attendant reduced spermatogenesis and hypopituitarism in patient management. Hence, we aim to evaluate the effects of mestorolone, an anabolic-androgenic steroid, on the histomorphometry of seminiferous tubules with serum hormonal and seminal analyses in adult male Sprague-Dawley rat. Twenty adult male Sprague dawley rats divided into two groups of 10 each. The treated group received 0.06 mg/g body weight/ day of mesterolone (proviron) by oral gavage for six weeks while the control group received equal volume of 0.9% normal saline per day.
    [Show full text]
  • PROVIRON Tablets
    The format of this leaflet was determined by the Ministry of Health and its content was checked and approved by it in July 2012 PRESCRIBING INFORMATION PROVIRON Tablets COMPOSITION Each tablet contains 25 mg mesterolone. ACTION -dihydro-testosterone, which is -methyl compound of 5Mesterolone is the 1 considered to be the proper active androgen in many androgen-dependent target organs. Proviron is an oral androgen preparation which has only a slight central inhibitory effect and, consequently, no restrictive effect on testicular function. Proviron balances a deficiency of androgen formation which begins to fall gradually with increasing age. Therefore, Proviron is suitable for the treatment of all conditions caused by deficient endogenous androgen formation. In the recommended therapeutic dosage, Proviron will not impair spermatogenesis. Proviron is especially well tolerated by the liver. PHARMACOKINETICS AND METABOLISM Following oral ingestion mesterolome is rapidly and almost completely absorbed in a wide dose range of 10 - 100 mg. The intake of Proviron generates maximum serum drug levels of 3.1 1.1 mg/ml after 1.6 0.2 hours. Thereafter drug levels in serum decrease with a terminal half-life of 12 13 hours. Mestorelone is bound to serum proteins by 98%. Binding to albumin accounts for 40% and binding to SHBG to 58%. Mestorelone is rapidly inactivated by metabolism. The metabolic clearance rate from serum accounts for 4.4 1.6 ml. min 1.kg1 . There is no renal excretion of unchanged drug. The main metabolite has been identified as 1 - methyl-androsterone, which - in conjugated form - accounts for 55 - 70% of renally excreted metabolites.
    [Show full text]
  • Interactions of Nandrolone and Psychostimulant Drugs on Central Monoaminergic Systems. National Institute for Health and Welfare (THL), Research 30
    Sanna Kailanto Sanna Kailanto Interactions of Nandrolone Sanna Kailanto and Psychostimulant Drugs RESEARCH Interactions of Nandrolone and RESEARCH Psychostimulant Drugs on Central on Central Monoaminergic Monoaminergic Systems Systems Monoaminergic Systems Monoaminergic Central on Drugs Psychostimulant and Nandrolone of Interactions This study had four main aims. First, it aimed to explore the effects of nandrolone decanoate on dopaminergic and serotonergic activities in rat brains. Second, it set out to assess whether nandrolone pre-exposure modulates the acute neurochemical and behavioral effects of psychostimulant drugs in experimental animals. A third aim was to investigate if AAS-pretreatment-induced changes in brain reward circuitry are reversible. Finally, the study was also intended to evaluate the role of androgen receptors in nandrolone’s ability to modulate the dopaminergic and serotonergic effects of stimulants. The results of the study show that AAS pretreatment inhibits the reward- related neurochemical and behavioral effects of amphetamine, MDMA and cocaine in experimental animals. Given that LMA, stereotyped behavior and accumbal outflow of DA and 5-HT are all related to reward, this study suggests that nandrolone, at tested doses, significantly affects the rewarding properties of stimulant drugs. Furthermore, it seems that these effects could be long- lasting and that the ability of nandrolone to modulate reward-related effects of stimulants depends on AR or ER activation. .!7BC5<2"HIFILD! National Institute for Health and Welfare P.O. Box 30 (Mannerheimintie 166) FI-00271 Helsinki, Finland Telephone: +358 20 610 6000 30 ISBN 978-952-245-258-0 www.thl.fi 30 2010 30 Sanna Kailanto Interactions of Nandrolone and Psychostimulant Drugs on Central Monoaminergic Systems Academic dissertAtIoN To be presented with the permission of the Faculty of Biological and Environmental Sciences, University of Helsinki, for public examination in the Arppeanum auditorium, Helsinki University Museum, Snellmaninkatu 3, Helsinki, on April 29nd, at 12 o’clock noon.
    [Show full text]
  • Diagnosis and Treatment of Testosterone Deficiency
    INTERNATIONAL CONSULTATION ON SEXUAL MEDICINE Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015) Mohit Khera, MD, MBA, MPH,1 Ganesh Adaikan, PhD, DSc,2 Jacques Buvat, MD,3 Serge Carrier, MD,4 Amr El-Meliegy, MD,5 Kostas Hatzimouratidis, MD,6 Andrew McCullough, MD,7 Abraham Morgentaler, MD,8 Luiz Otavio Torres, MD,9 and Andrea Salonia, MD10 ABSTRACT Introduction: Testosterone deficiency (TD), also known as hypogonadism, is a condition affecting a substantial proportion of men as they age. The diagnosis and management of TD can be challenging and clinicians should be aware of the current literature on this condition. Aim: To review the available literature concerning the diagnosis and management of TD and to provide clinically relevant recommendations from the Fourth International Consultation for Sexual Medicine (ICSM) meeting. Methods: A literature search was performed using the PubMed database for English-language original and review articles published or e-published up to January 2016. Main Outcome Measures: Levels of evidence (LoEs) and grades of recommendations are provided based on a thorough analysis of the literature and committee consensus. Results: Recommendations were given for 12 categories of TD: definition, clinical diagnosis, routine measurement, screening questionnaires, laboratory diagnosis, threshold levels for the biochemical diagnosis of TD, prostate cancer, cardiovascular disease, fertility, testosterone (T) formulations, alternatives to T therapy, and adverse events and monitoring. A total of 42 recommendations were made: of these, 16 were unchanged from the Third ICSM and 26 new recommendations were made during this Fourth ICSM. Most of these recommendations were supported by LoEs 2 and 3.
    [Show full text]
  • Interactions of Nandrolone and Psychostimulant Drugs on Central Monoaminergic Systems
    Sanna Kailanto Sanna Kailanto Interactions of Nandrolone Sanna Kailanto and Psychostimulant Drugs RESEARCH Interactions of Nandrolone and RESEARCH Psychostimulant Drugs on Central on Central Monoaminergic Monoaminergic Systems Systems Monoaminergic Systems Monoaminergic Central on Drugs Psychostimulant and Nandrolone of Interactions This study had four main aims. First, it aimed to explore the effects of nandrolone decanoate on dopaminergic and serotonergic activities in rat brains. Second, it set out to assess whether nandrolone pre-exposure modulates the acute neurochemical and behavioral effects of psychostimulant drugs in experimental animals. A third aim was to investigate if AAS-pretreatment-induced changes in brain reward circuitry are reversible. Finally, the study was also intended to evaluate the role of androgen receptors in nandrolone’s ability to modulate the dopaminergic and serotonergic effects of stimulants. The results of the study show that AAS pretreatment inhibits the reward- related neurochemical and behavioral effects of amphetamine, MDMA and cocaine in experimental animals. Given that LMA, stereotyped behavior and accumbal outflow of DA and 5-HT are all related to reward, this study suggests that nandrolone, at tested doses, significantly affects the rewarding properties of stimulant drugs. Furthermore, it seems that these effects could be long- lasting and that the ability of nandrolone to modulate reward-related effects of stimulants depends on AR or ER activation. .!7BC5<2"HIFILD! National Institute for Health and Welfare P.O. Box 30 (Mannerheimintie 166) FI-00271 Helsinki, Finland Telephone: +358 20 610 6000 30 ISBN 978-952-245-258-0 www.thl.fi 30 2010 30 Sanna Kailanto Interactions of Nandrolone and Psychostimulant Drugs on Central Monoaminergic Systems Academic disSertAtIoN To be presented with the permission of the Faculty of Biological and Environmental Sciences, University of Helsinki, for public examination in the Arppeanum auditorium, Helsinki University Museum, Snellmaninkatu 3, Helsinki, on April 29nd, at 12 o’clock noon.
    [Show full text]
  • Legally Defensible Steroid Testing Services
    LGC in drug and alcohol testing Legally defensible steroid testing services Anabolic steroid misuse has Anabolic steroids, technically known as anabolic- historically been associated with sport androgenic steroids (AAS), are drugs that are structurally related to the naturally produced and doping scandals over the past steroid testosterone. They increase protein within 25 years. More recently, due in part cells, especially in skeletal muscles. Anabolic to their ready availability over the steroids also have androgenic and virilising internet both as steroid preparations properties, including the development and and as constituents of steroid based maintenance of masculine characteristics such as the growth of the vocal cords, testicles (primary nutritional supplements, the misuse of sexual characteristics) and body hair (secondary anabolic steroids has spread to wider sexual characteristics). areas of society including regular gym users and sub-elite sportspeople. www.lgcgroup.com/steroids • [email protected] Science for a safer world Brazil • Bulgaria • China • Czech Republic • France • Germany • Hungary • India • Ireland • Italy • Netherlands Poland • Romania • Russia • Scandanavia • South Africa • Spain • Turkey • United Kingdom • USA No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or any retrieval system, without the written permission of the copyright holder. © LGC Limited, 2014. All rights reserved. 3995/LB/0814 Anabolic steroids were first synthesized in the and for cause workplace screen for anabolic Bolasterone 1930s, and are now used therapeutically in steroids. This premier service is comparable to that Boldenone medicine to stimulate bone growth and appetite, currently provided by WADA accredited laboratories Boldione Calusterone induce male puberty and treat chronic wasting supporting doping control programmes in sport.
    [Show full text]
  • CHAPTER I: INTRODUCTION Use of Steroids in Sports Such
    CHAPTER I: INTRODUCTION The drugs are artificially derived from the main male hormone Testosterone. Testosterone is important for promoting and maintaining muscle growth and developing secondary male sex characteristics, such as a deepening voice and facial hair. Anabolic steroids, also called Anabolic-Androgenic Steroids (AASs), can build muscle and improve athletic performance, but they can also have significant adverse effects, especially when used incorrectly. Long-term, non-medical uses are linked to heart problems, unwanted physical changes, and aggression. There is growing concern worldwide about the non- medical use of steroids and its effects. Street names include Arnolds, gym candy, pumpers, roids, and stackers. AASs are synthetic versions of the primary male hormone, testosterone. They affect many parts of the body, including the muscles, bones, hair follicles, liver, kidneys, blood, immune system, reproductive system and the central nervous system. During puberty, increases in testosterone levels enable the development of characteristics such as facial and body hair growth, increased height and muscle mass, a deepening voice, and the sex drive. Testosterone can also contribute to competitiveness, self-esteem, and aggressiveness. Continuous use of AASs can lead to problems such as tolerance. They may even cause the body to stop producing its own testosterone. Some people use AASs continuously, but others try to minimize their possible adverse effects through different patterns of use. Use of Steroids In Sports Such As: 1. Cycling: The person takes AASs in cycles of 6 to 12 weeks known as the "on" period, followed by 4 weeks to several months off. 2. Stacking: Users combine several different types of steroids or incorporate other supplements in an attempt to maximize the effectiveness of the steroids.
    [Show full text]
  • Hepatotoxicity Associated with Illicit Use of Anabolic Androgenic Steroids in Doping
    Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2017; 21 (1 Suppl): 7-16 Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping R. SOLIMINI, M.C. ROTOLO, L. MASTROBATTISTA, C. MORTALI, A. MINUTILLO, S. PICHINI, R. PACIFICI, I. PALMI Department of Therapeutic Research and Medicines Evaluation, Drug Abuse and Doping Unit, Istituto Superiore di Sanità, Rome, Italy Abstract. – Anabolic Androgenic Steroids Since then , several synthetic analogs of testos - (AAS) abuse and misuse is nowadays a harmful terone, known as Anabolic Androgenic Steroids habit involving both professional or recreational (AAS) or designer steroids (e.g . methyltestos - athletes, as well as general population. AAS are also frequently present in over-the-counter di - terone in 1935 , nandrolone in 1950 and 1953, etary supplements without being declared in the testosterone esters from mid-1950s, stanozolol list of ingredients, leaving consumers unaware and oxymetholone in 1959 , oxandrolone in 1962) of the risks of adverse effects. Indeed, health have been produced in the attempt to minimize risks of AAS consumption in pharmaceutical the androgenic effects and improve the anabolic preparations or dietary complements seem still ones 1,2,7-9 . However , a successful complete sepa - underestimated and under-reported. The variety of complications due to AAS misuse involves ration of the anabolic and the androgenic proper - cardiovascular, central nervous, musculoskeletal ties has never been realized in the synthetic de - and genitourinary systems of both males and fe - rivatives of testosterone 1,2,10,11 . Among those, nan - males; psychiatric and behavioral effects, dam - drolone was the first compound which showed a ages to metabolic system, skin and mainly liver.
    [Show full text]